Is regional anaethesia of the hip preferable over traditional analgesia in the acute stage of the management of patients with a fracture of the hip?

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-003326-27-SE

Enrollment

132

Registered

2011-08-15

Start date

2011-12-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fracture of the hip

Interventions

Trade Name: Narop Product Name: Narop Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Infiltration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: fracture of the hip Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 132

Exclusion criteria

Exclusion criteria: multiple fractures, delay (more than 12 hours) from the time of injury until admission to the hospital, local infections, hypersensitivity to local analgetica, cognitive impairment

Design outcomes

Primary

Measure	Time frame
Main Objective: pain management in patients with a fracture of the hip;Secondary Objective: medical complications, cost of treatment;Primary end point(s): pain;Timepoint(s) of evaluation of this end point: 3, 6, 12 and 24 hours	—

Secondary

Measure	Time frame
Secondary end point(s): medical complications (pressure ulcers, pneumonia), cost of treatment	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026